Ildong Pharmaceutical revealed its plans to export its cardiovascular active pharmaceutical ingredient (API) - benidipine hydrochloride to Guangzhou Tosun Pharmaceutical in China.

Benidipine hydrochloride is a calcium channel blocker (CCB) drug that blocks the movement of calcium ions involved in the contraction of blood vessels and heart muscle to dilate blood vessels. It also relieves the burden on the heart and is mainly used to treat hypertension and angina pectoris.

Under the accord, Ildong will supply Tosun with benidipine hydrochloride, and Tosun will distribute and sell the API to related companies in China.

"Ildong's benidipine hydrochloride is synthesized and manufactured using our own technology and is recognized for its excellence as it is exported to countries such as Japan. In China, the number of cardiovascular patients is steadily increasing, and related markets such as demand for therapeutics have great potential for growth," said an Ildong official.

With this agreement, Ildong plans to expand its business scope and focus on entering the Chinese market.